Retour aux projets

44271.1 IP-LS

44271.1 IP-LS

Résumé

EZH2 Inhibitors: a new treatment opportunity with disease modifying potential for people with hereditary blindness

Textes supplémentaires

Abstract

No generic treatments are available for inherited retinal dystrophies resulting in blindness. We found that the inhibition of an enzyme involved in epigenetic modifications markedly improved cell survival, so we aim to determine the best existing drug to delay blindness in human in the near future.

Participants

Yvan Arsenijevic

Kontaktperson

yvan.arsenijevic@fa2.ch

Fondation Asile des aveugles Yvan Arsenijevic Av. de France 15 1004 Lausanne VD CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2020-05-31
Date de fin
2022-03-31
Coûts totaux approuvés
CHF 356229.26
Section
60 Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T410 Pharmaceuticals and related technologies 100.0%